PURPOSE OF REVIEW: Increasing number of people living with HIV (PLHIV) will require expanded access to health services. Countries need robust and contemporary strategic information on the cost of care to monitor and evaluate the effectiveness, efficiency, equity, and acceptability of services. Published HIV cost literature from July 1999 to December 2008 was reviewed. Articles were identified using specific databases and scored, based on explicit criteria relating to the services covered, utilization data, cost data used and quality of the study. RECENT FINDINGS: One hundred and fifteen articles were identified, 47% came from North America, 29% from Europe, 17% from Africa and 8% from Asia; no studies from Latin America could be identified. The mean score across all studies was 33.7 out of a maximum of 64, with a median of 34 and a range of 11-51. Mean score did not change significantly over time (Pearson's R8 = 0.3; P > 0.05). SUMMARY: Great variation was observed in the methods used to estimate cost data across the studies identified, including range of services, patients covered and outcomes costed. Progress in the quantity and quality of studies published since 1999 has been limited. More consistent costing methods and more comprehensive coverage - both by country and level of care - are needed in order for policymakers and other stakeholders to be able to optimally monitor and evaluate the cost and cost-effectiveness of country services for HIV treatment and care, especially as population costs are likely to increase with more PLHIV on antiretroviral therapy.
PURPOSE OF REVIEW: Increasing number of people living with HIV (PLHIV) will require expanded access to health services. Countries need robust and contemporary strategic information on the cost of care to monitor and evaluate the effectiveness, efficiency, equity, and acceptability of services. Published HIV cost literature from July 1999 to December 2008 was reviewed. Articles were identified using specific databases and scored, based on explicit criteria relating to the services covered, utilization data, cost data used and quality of the study. RECENT FINDINGS: One hundred and fifteen articles were identified, 47% came from North America, 29% from Europe, 17% from Africa and 8% from Asia; no studies from Latin America could be identified. The mean score across all studies was 33.7 out of a maximum of 64, with a median of 34 and a range of 11-51. Mean score did not change significantly over time (Pearson's R8 = 0.3; P > 0.05). SUMMARY: Great variation was observed in the methods used to estimate cost data across the studies identified, including range of services, patients covered and outcomes costed. Progress in the quantity and quality of studies published since 1999 has been limited. More consistent costing methods and more comprehensive coverage - both by country and level of care - are needed in order for policymakers and other stakeholders to be able to optimally monitor and evaluate the cost and cost-effectiveness of country services for HIV treatment and care, especially as population costs are likely to increase with more PLHIV on antiretroviral therapy.
Authors: Larry W Chang; Joseph Kagaayi; Gertrude Nakigozi; David Serwada; Thomas C Quinn; Ronald H Gray; Robert C Bollinger; Steven J Reynolds; David Holtgrave Journal: AIDS Care Date: 2012-09-13
Authors: Kathryn E McCollister; Christy K Scott; Michael L Dennis; Derek M Freitas; Michael T French; Rodney R Funk Journal: J Offender Rehabil Date: 2014-09-16
Authors: Reuben Granich; Ying-Ru Lo; Amitabh B Suthar; Marco Vitoria; Rachel Baggaley; Carla Makhlouf Obermeyer; Craig McClure; Yves Souteyrand; Jos Perriens; James G Kahn; Rod Bennett; Caoimhe Smyth; Brian Williams; Julio Montaner; Gottfried Hirnschall Journal: Curr HIV Res Date: 2011-09 Impact factor: 1.581
Authors: Bruce A Larson; Margaret Bii; Sarah Henly-Thomas; Kelly McCoy; Fredrick Sawe; Douglas Shaffer; Sydney Rosen Journal: J Int AIDS Soc Date: 2013-01-02 Impact factor: 5.396